Clinical Trial Update: Study of Maraviroc (MVC) and Epzicom (ABC/3TC) Once-Daily in ART-Naive & First Switch Patients

View source ↗

Summary

A completed study evaluating once-daily maraviroc with Epzicom (abacavir/lamivudine) in ART-naive and first-switch HIV patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Epzicom (abacavir/lamivudine)
• Selzentry (Maraviroc)

Snippet

Sponsor: Nicholaos C Bellos, MD | Conditions: Drug-induced Hypotension | Status: COMPLETED